Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Classical hematology 1

Conditions

Thrombocytopenia 4Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Solid Tumor 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Hodgkin Disease 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 115fludarabine phosphate 67Mycophenolic Acid 62Etoposide 61Peripheral Blood Stem Cell Transplantation 58Tacrolimus 55Melphalan 48Filgrastim 48Busulfan 48Whole-Body Irradiation 47Doxorubicin 46Radiotherapy 42fludarabine 38Cyclosporine 38Brentuximab Vedotin 38Vinblastine 35Granulocyte Colony-Stimulating Factor 35Antilymphocyte Serum 30Methotrexate 29Dacarbazine 29Gemcitabine 28Rituximab 26Nivolumab 25Prednisone 24Bleomycin 24Vincristine 22pembrolizumab 21Carmustine 21Cytarabine 20thymoglobulin 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hodgkin Disease × romiplostim × Clear all
NCT04478123 2024-02-14

Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
62 enrolled 7 charts
Classical hematologyLymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡